--- title: "Cancer Young Female Adults Ovarian Damage Prevention ALTE2131 | Sutter Health" description: "Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer" url: "https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Cancer Young Female Adults Ovarian Damage Prevention ALTE2131 # Cancer Young Female Adults Ovarian Damage Prevention ALTE2131 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT06513962). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer ![Sandra K Baril, M.D.](https://dyn.mktgcdn.com/p/LeDczJiBVc-OKMwdWQTzaO-WX-HJKEXWeWf47e1fMY4/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Sandra K Baril, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/sandra-k-baril-md-2016036488) ## Sub-Investigators [Janice K Ryu, M.D.](https://www.sutterhealth.org/research/investigators/janice-k-ryu-md-2016036552) , [Rachel Bito, M.D.](https://www.sutterhealth.org/research/investigators/rachel-bito-md-2070392186) , [Saunders C Hsu, M.D., MPH](https://www.sutterhealth.org/research/investigators/saunders-c-hsu-md-mph-1049681145) ## Email us to enroll - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Cancer%20Young%20Female%20Adults%20Ovarian%20Damage%20Prevention%20ALTE2131%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Interventional Myeloma EQUATE EAA181](https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964) Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446) Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-idecabtagene-vicleucel-bb2121-eap-001-2062975937) Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release **Status:** Coming Soon - Clinical trial ### [Neoadjuvant Hodgkin Lymphoma COG AHOD2131](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-hodgkin-lymphoma-cog-ahod2131-2080025103) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Large B-Cell Lymphoma Alpha3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994) A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Cancer Young Female Adults Ovarian Damage Prevention ALTE2131"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841#medicalwebpage","name":"Cancer Young Female Adults Ovarian Damage Prevention ALTE2131","description":"Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer","url":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841","inLanguage":"en-US","dateModified":"2026-08-10","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841#breadcrumblist"},"mentions":[{"@type":"Person","name":"Sandra K Baril, M.D.","url":"https://www.sutterhealth.org/research/investigators/sandra-k-baril-md-2016036488","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841#medicaltrial","name":"Cancer Young Female Adults Ovarian Damage Prevention ALTE2131","alternateName":"Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer","url":"https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841","description":"Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer","identifier":"NCT06513962","code":{"@type":"MedicalCode","codeValue":"NCT06513962","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT06513962","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Hematologic Cancer"},{"@type":"MedicalCondition","name":"Lymphoma, Pediatric"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```